US Capitol Capsule: What's in a name? FDA mulls unique versus same for biosimilars
This article was originally published in Scrip
Executive Summary
Among the issues that popped up throughout an 11 May all-day US FDA meeting was whether biosimilars should share the same international nonproprietary name as the innovator biologics on which they are based or if they should have unique names.